New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:51 EDTLBIOLion Biotechnologies deal increases visibility, says Roth Capital
After Lion Biotechnologies (LBIO) and Immunocore entered into an agreement to co-discover and co-develop novel T-cell based cancer therapies. Roth Capital thinks the deal increases the visibility for T-cell therapies and is positive for Lion Biotechnologies. The firm sees the deal as an indication that large drug companies remain interested in the T-cell based immunotherapy space, and it thinks that Lion is well-positioned in the space. The firm reiterates a $20 price target and Buy rating on Lion.
News For LBIO From The Last 14 Days
Check below for free stories on LBIO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
08:51 EDTLBIOLion Biotechnologies deal increases visibility, says Roth Capital
After Lion Biotechnologies (LBIO) and Immunocore entered into an agreement to co-discover and co-develop novel T-cell based cancer therapies. Roth Capital thinks the deal increases the visibility for T-cell therapies and is positive for Lion Biotechnologies. The firm sees the deal as an indication that large drug companies remain interested in the T-cell based immunotherapy space, and it thinks that Lion is well-positioned in the space. The firm reiterates a $20 price target and Buy rating on Lion.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use